Further into the future, patients suffering from any type of virus could be cured with DRACO
Newly emerging flu viruses could soon be countered by a treatment that Draper Laboratory is developing that “traps” viruses before they can infect host cells.
Further into the future, patients suffering from any type of virus could be cured with DRACO, a drug also under development at Draper that is designed to rapidly recognize and eliminate cells infected by virtually any virus.
Both methods could help safeguard against bioterrorist attacks and naturally occurring pandemics in a manner that is unlikely to lead to treatment-resistant strains. Initial testing on the treatments, which each use tiny, non-toxic particles that can be injected, inhaled, or eaten, has shown them to be effective and safe against a multitude of strains of disease.
Nanotraps, which could be taken at the first sign of infection or exposure, is likely the first of the products ready for use, and is expected to begin clinical trials in two to five years, according to Jim Comolli, who leads the research on the effort at Draper.
Nanotraps, developed by a team of researchers from Draper, MIT, the University of Massachusetts Medical School, and the University of Santa Barbara, are nanoparticles that act as viral “traps” using specific molecules found naturally within the human body. A paper published in the March issue of Journal of Biological Chemistry detailed their findings.
The nanotraps look like the surface of a cell, with numerous carbohydrate molecules attached that closely resemble those targeted by flu viruses in the human respiratory system. These molecules, initially characterized in the Sasisekharan Lab at MIT, act as bait for the flu virus, which bind to the nanotrap instead of a host cell and are cleared away with mucus, preventing infection, Comolli said.
The research team has demonstrated in the laboratory that the nanotraps effectively countered multiple influenza strains able to infect humans and went on to show nanotraps protected mice infected with the flu. They have also developed additional particles geared toward other types of respiratory viruses.
Nanotraps, unlike most vaccines, are not strain specific and are designed to be effective against newly emerging strains of human-adapted influenza virus. Since nanotraps mimic a fundamental step in the viral life cycle – the binding of the virus to a host cell’s receptor – nanotraps may offer an opportunity to treat devastating infectious diseases without causing the development of treatment resistance, Comolli said.
The nanotrap molecule is composed mainly of compounds found naturally in the human body so it is likely to be safe as an inhalant, topical solution, or intravenous treatment and inexpensive to manufacture. With further development, nanotraps have the potential to treat a large range of infectious diseases because the attached carbohydrates can be tuned for other viruses such as HIV, Respiratory Syncytial Virus (RSV), and Herpes Simplex Virus (HSV), as well as bacteria and toxins.
The work was originally funded by the Defense Advanced Research Projects Agency (DARPA) to address emerging pandemics or bioweapons targeting US troops; Draper is continuing the research with the intent of applying it more broadly to the civilian community.
While nanotraps could be customized to treat a variety of viruses, another project underway at Draper, DRACO could do so with a single approach. DRACO is a unique therapeutic drug that should be effective against a very broad spectrum of viruses, just as existing antibiotics are effective against a broad range of bacterial infections. DRACO could be ready for human clinical trials in five to 10 years, according to Todd Rider, who leads the research at Draper.
DRACO (Double-stranded RNA Activated Caspase Oligomerizer) is designed to detect cells that have been virally infected and then eradicate only the infected cells, rapidly ending the infection. DRACO has proven effective in vivo against influenza and three hemorrhagic fever viruses, and in vitro against 15 different viruses – including common cold viruses, the H1N1 influenza strain, adenoviruses, a mouse polio virus, dengue fever, and stomach viruses, among others. It has also been tested and proven safe in both mice and 11 different human and animal cell types representing organs like the heart, lungs, liver, and kidney, among others.
DRACO is designed to be attracted to a specific type of RNA exclusive to viral infections – long double-stranded RNA, or dsRNA. Detecting this dsRNA in a human or animal cell indicates that that host cell has been taken over by a virus and is now in the process of creating more viruses. DRACO enters cells and attaches itself to any dsRNA. Once two or more DRACOs attach to the dsRNA, they interact with one another and activate a natural self-destruct switch inside the infected cell, terminating the infected cell and the virus that it was helping to reproduce.
The Latest on: Viral infections
via Google News
The Latest on: Viral infections
- Tailored T-cells safe, may be effective in preventing and treating multiple viral infectionson November 18, 2019 at 11:22 am
Tailored T-cells specially designed to combat a half dozen viruses are safe and may be effective in preventing and treating multiple viral infections, according to research led by Children's National ...
- Article proposes important mucin link between microbial infections and many cancerson November 18, 2019 at 9:59 am
"Now it is known that about 20% of all malignancies, especially epithelial malignancies, are associated with some sort of infection, viral or bacterial, persistent inflammation being the root cause" ...
- International HIV Experts Call for Focus on Quality of Life Beyond Viral Suppressionon November 18, 2019 at 2:52 am
Middle East and Africa Infectious Diseases and Vaccines Therapeutic Area Lead, Janssen-Cilag International NV. “The ultimate aim of this initiative is to provide clear, detailed guidelines and tools ...
- Viral ‘Smart Bombs’ Are Becoming Weapons Against Superbugson November 18, 2019 at 2:00 am
Four hospitals had denied Grimwood a transplant because of the infection, which had required some 40 surgical scrapings over three years and left him with a Key lime-size open wound in his chest.
- The U.S. needs extra action to eliminate viral hepatitis, the nation’s deadliest infectious diseaseon November 15, 2019 at 1:59 am
At the 2008 liver diseases meeting in San Francisco, which I was attending as a longtime viral hepatitis advocate, Dr. Nezam Afdhal, who is now the chief of the division of gastroenterology, ...
- VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infectionon November 14, 2019 at 4:20 pm
“Chronic HBV has long been considered one of the most challenging viral infections to treat, due to its complex life cycle once it takes hold in the liver,” said Jeff Baxter, President and CEO of VBI.
- How $6 million could help a small Peninsula company spot deadly infectionson November 14, 2019 at 11:49 am
Inflammatix already is working on using the system, called HostDx, in sepsis, a life-threatening condition caused by the body's reaction to a viral or bacterial infection. The company plans to start a ...
- Girl, 2, misdiagnosed with 'viral infection' actually has extremely rare form of canceron November 14, 2019 at 10:39 am
A family have launched an appeal after their two-year-old who was wrongly diagnosed with a highly rare form of cancer - after originally being told she had a viral infection The parents of Isla ...
- Molecular Scissors Could Help Keep Some Viral Illnesses At Bayon November 13, 2019 at 8:25 am
It's not easy to treat viral infections. Just ask anyone with a bad cold or a case of the flu. But scientists in Massachusetts think they may have a new way to stop viruses from making people sick by ...
- Pulmonary monocytes interact with effector T cells in the lung tissue to drive T RM differentiation following viral infectionon November 13, 2019 at 3:57 am
Access to this article is not available. Villadangos, J. A. & Heath, W. R. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the ...
via Bing News